ApconiX Welcomes Simon Craige to the Team
ApconiX is delighted to welcome Simon Craige to the team.
Simon has over 15 years’ nonclinical and toxicology experience working in several medical and pharmaceutical organisations across multiple disciplines including small molecules, vaccines, biologics, and medical devices. He has experience of a diverse range of therapeutic areas including oncology, CNS, ocular and dermal in drug discovery and development within both biotech and CROs.
Simon studied at the University of Birmingham for a BSc in Biological Sciences (Microbiology) before going on to study for a Master’s degree in toxicology. He joined Charles River Laboratories as a trainee study director in reproductive toxicology, moving onto Sequani as a study director in general and reproductive toxicology. Simon relocated to Switzerland where he worked at AC Immune in Lausanne designing, preparing, and implementing in vivo and in vitro studies to meet regulatory requirements for pre-IND/Clinical Trial Application (CTA) and IND/CTA submission of biologics and small molecules.
Simon joined Fontem Ventures, an Imperial Tobacco Company, to project manage testing programmes for innovative non-tobacco products. As a senior toxicologist based within the consulting services group of North American Science Associates (NAMSA) he prepared, risk assessments, gap analyses, evaluation plans and reports, in compliance with ISO 10993-1, ISO 10993-17 and ISO 14971, for submission to FDA and other regulatory agencies. Simon was also, previously, a non-clinical manager at Syneos Health.
Simon has been a European Registered Toxicologist since 2012 and American Board Registered Toxicologist since 2014. He’s currently a member of the Society of Toxicology (SOT), American College of Toxicology (ACT), Swiss Society of Toxicology (SST) and European Teratology Society (ETS).
Dr Richard Knight, Director and Co-founder of ApconiX commented, “It’s great to have an experienced toxicologist like Simon join ApconiX. Having worked in biotech and at a CRO, and supported small molecules, biologics and medical devices, his breadth of experience will really complement and extend our capabilities”.